Paras Biopharmaceuticals Finland Oy
Paras Biopharmaceuticals Finland Oy
Development of Recombinant expression systems and process technologies for biologics and biosimilars - Due to its own technologies, Paras Biopharmaceuticals has achieved efficient and cost-effective ways which would help in the efficient production of some high value biosimilars. This development is based on Paras Bio-pharmaceuticals’ proprietary technology platform which includes Diabrid ® , Noblecleav ® , Biomultifold ® and Cytofold StructQuant ® technologies.
- Type
- Manufacturer
- Location
- Finland
- Website
- http://parasbiopharma.com
- Categories
- Pharmaceutical Manufacturing
Listed in a source registry
Verified facts
- domain-registered (green), checked 2026-08-02 Domain registry record
- supervised-operator (green), checked 2026-08-14 Tukes register of operators (Finnish Safety and Chemicals Agency)
- operating-permit (green), checked 2026-08-08 EEA Industrial Emissions Portal (IED), EU-wide permit register
- facility-registered (green), checked 2026-08-16 European Industrial Emissions Portal (E-PRTR / IED), European Environment Agency
- registry-id-verified (green), checked 2026-08-14 Finnish Patent and Registration Office, Trade Register (PRH/YTJ open data)
- registry-activity (green), checked 2026-08-14 Finnish Patent and Registration Office, Trade Register (PRH/YTJ open data)
- registered-address (green), checked 2026-08-14 Finnish Patent and Registration Office, Trade Register (PRH/YTJ open data)
- registry-active-global (green), checked 2026-07-09 Finnish Patent and Registration Office (PRH)
- tax-filing-active (green), checked 2026-08-14 Finnish Tax Administration, public corporate tax data 2024 (Verohallinto)
Import rules for these goods
- Medicines imported into the EU must come from a site holding an EU GMP certificate, and the importer needs a manufacturing/import authorisation. European Medicines Agency (GMP)